Isocitrate dehydrogenase (IDH) mutation status is currently one of the most prominent biomarkers, most often occurring in World Health Organization (WHO) grades II and III gliomas (formerly known as lower-grade gliomas) [2,3]. Here, IDH1 is linked to central nervous system cancer.